Business Wire

PERSONETICS

31.1.2023 08:01:43 CET | Business Wire | Press release

Share
European banks say that traditional money management tools are not meeting expectations

Personetics, the global leader in financial data-driven customer engagement for financial services today released a report titled Spotlight On Europe: Banks Need To Nurture Customers’ Financial Well-Being. The report, based on a study conducted by Forrester Consulting on behalf of Personetics, details the opportunities and challenges associated with leveraging money management tools to enhance customer engagement and increase lifetime value.

“Now more than ever, customers demand greater control of their finances and expect their banks to deliver real-time, financial data-driven personalised advice and long-term planning,” said Dorel Blitz, VP of Strategy & Business Development at Personetics. “Yet Forrester’s report reveals that existing Personal Financial Management (PFM) tools are neither meeting customer expectations nor delivering business impact for banks. The banks that will thrive are those which will take advantage of the opportunity to provide advanced and proven money management capabilities.”

Forrester based its conclusions on responses from key banking decision-makers. The report shows that while most banks offer basic PFM and money management capabilities there is a growing, urgent need for both banks and their customers to “evolve their approach in order to successfully raise customers’ levels of financial well-being.”

For example, the European survey revealed disappointingly low levels of customer adoption and engagement with digital money management tools. Although nearly three-quarters (73%) of bankers say they already offers customers some sort of digital money management tool, 77% state that fewer than half of their customers actively use these tools.

The report found that adoption is low because existing money management tools fail to deliver tangible outcomes for customers. Today’s money management tools follow a one-size-fits-all approach, meaning they put too much onus on the end user and fail to help customers achieve their financial goals.

Mr. Blitz added: “The good news is that banks are alive to the issues they face. Now it’s a matter of finding the right path forward, through proactive, hyper-personalised solutions at scale that can make a difference today.”

Below are the core findings across Europe.

Banks have high expectations for money management solutions.

When asked about the benefits of implementing digital technologies for this purpose, the top three benefits were increased customer engagement (47%), increased revenue through upsell and cross-sell (43%) and new customer acquisition (43%).

Traditional PFM fails to deliver effective customer outcomes.

One of the main challenges in deploying these digital capabilities is the absence of an enterprise-wide approach to enhancing customer outcomes. Just over half of banks say they can provide sufficient personalised financial insights and advice based on customers’ financial data. This leaves a significant number of banks without the means to deliver competitive and appealing offers and products for their customers.

A major opportunity exists for innovative banks.

Banks should use an advanced money management platform to deliver business impact, increase revenue, profitability, and customer lifetime value. To do this, financial institutions need to partner with the right vendor and invest in advanced capabilities, adopt a financial data-driven approach, and deliver solutions that customers need when they need them.

Read the full report here.

About Personetics

Personetics is a global financial data-driven personalised customer engagement platform for financial services. The company’s mission is to shape the future of “Self-Driving Finance,” where financial institutions can proactively help consumers improve their financial well-being and achieve financial goals.

Personetics serves more than 100 financial institutions in 32 global markets and reaches 140 million customers. The company is backed by leading venture capital and private equity investors, with offices in New York, London, Tel Aviv, Singapore, Tokyo, Paris, Spain, and Australia.

Learn more at personetics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005691/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye